Schizoaffective Disorder: Clinical Trials

41 trials for Schizoaffective Disorder, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 3 terminated, 2 unknown, 1 not yet recruiting. 41 Phase 1, 8 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 141Completed 34, Terminated 3, Unknown 2, Not yet recruiting 1, Suspended 1
Phase 28Completed 6, Suspended 1, Terminated 1

Follow Schizoaffective Disorder: new trials by email Literature Review of Schizoaffective Disorder trials Research Report on Schizoaffective Disorder

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Longitudinal PET Imaging of Antipsychotic Binding to the Dopamine-3 Receptor in Schizophrenia
Brexpiprazole, Cariprazine, [11C] PHNO - Schizoaffective Disorder, Schizophreniform Disorder
Phase 1Not yet recruitingNew York State Psychiatric Institute1002026-12-012026-07-20
Accelerated TMS in Psychosis
repetitive Transcranial Magnetic Stimulation (rTMS) - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2SuspendedBeth Israel Deaconess Medical Center202022-11-292026-04-22
Minocycline Augmentation of Clozapine for Treatment Resistant Schizophrenia
Minocycline - Schizophrenia, Schizoaffective Disorder
Phase 1UnknownPakistan Institute of Living and Learning602022-08-302022-04-29
M1 Schizophrenia PET Study
11C-EMO - A Novel PET Radiotracer for Muscarinic M1 Receptor, PET Scan - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedYale University182021-04-202024-11-12
BXCL501 for Agitation in Schizophrenia
Dexmedetomidine Hydrochloride, Placebos - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedYale University112020-03-092025-07-23
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
N-acetylcysteine (NAC), Placebo, Tryptophan - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2CompletedUniversity of Maryland, Baltimore882020-01-202026-02-11
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe - Schizo Affective Disorder, Schizophrenia
Phase 1CompletedLuye Pharma Group Ltd.482018-12-122019-08-13
Clinical Trial of AVL-3288 in Schizophrenia Patients
AVL-3288, Placebo - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedNew York State Psychiatric Institute242016-11-012019-01-22
Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder
Lu AF35700 (10 mg/day), Lu AF35700 (30 mg/day), Quetiapine (Seroquel XR® 800 mg/day) - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedH. Lundbeck A/S1192016-09-012019-09-12
A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder
Aripiprazole Lauroxil - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedAlkermes, Inc.472015-12-012016-07-14
OnTrack>An Online Role-Playing Game: A Small Business Innovation Research (SBIR) Grant
Behavioral/Attitudinal OnTrack Role-Playing Game - Psychosis, Schizoaffective Disorder
Phase 1CompletedCenter for Social Innovation, Massachusetts192015-06-012016-07-27
Safety and PK Trial With Injectable ZX003 (Risperidone-SABER®) Compared to Risperdal® Consta® in Stable Schizophrenia
ZX003 (Risperidone-SABER®), Risperdal Consta, Oral Risperidone - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedZogenix, Inc.602015-02-012022-10-31
Bioavailability of LY03004 and Risperdal® Consta®
LY03004, Risperdal® Consta® - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedLuye Pharma Group Ltd.1082014-09-012015-03-04
An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder
Risperdal® Consta®, LY03004 - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedLuye Pharma Group Ltd.162014-07-012015-06-18
RCT of Methotrexate Added to Treatment As Usual in Schizophrenia
Methotrexate - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedPakistan Institute of Living and Learning922013-12-012015-09-22
Examining Dose-Related Effects of Oxytocin on Social Cognition Across Populations
Syntocinon 24 Intranasal Units (IU), Syntocinon 40 Intranasal Units (IU), Intranasal Placebo - Borderline Personality Disorder, BPD
Phase 1TerminatedMaria de las Mercedes Perez Rodriguez922013-09-012022-10-10
Effectiveness of Adherence Therapy for Schizophrenia
Adherence therapy - Schizophrenia, Schizophreniform Disorder
Phase 1 / Phase 2CompletedThe Hong Kong Polytechnic University1342013-05-012016-02-19
Pharmacokinetic, Safety, and Tolerability Study of Risperidone ISM® at Different Dose Strengths
Risperidone ISM 50 mg, Risperidone ISM 75 mg, Risperidone ISM 100 mg - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedRovi Pharmaceuticals Laboratories362013-04-012023-10-23
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
LY03004 - Schizophrenia, Schizoaffective Disorder
Phase 1CompletedLuye Pharma Group Ltd.362013-03-012014-11-10
Kuvan in People With Schizophrenia and Schizoaffective Disorder
Kuvan, Multivitamin - Schizophrenia, Schizoaffective Disorder
Phase 1 / Phase 2CompletedNew York State Psychiatric Institute272012-10-012017-09-13

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Psychotic Disorders (41)  ·  Schizophrenia (40)  ·  Mood Disorders (4)  ·  Bipolar Disorder (3)  ·  Depressive Disorder, Major (2)  ·  Schizotypal Personality Disorder (2)  ·  Autism Spectrum Disorder (1)  ·  Borderline Personality Disorder (1)  ·  Central Nervous System Diseases (1)  ·  Depression (1)  ·  Depressive Disorder (1)  ·  Insulin Resistance (1)  ·  Marijuana Abuse (1)  ·  Mental Disorders (1)  ·  Obesity (1)

Broader conditions

Schizophrenia Spectrum and Other Psychotic Disorders (41)  ·  Mental Disorders (40)  ·  Bipolar and Related Disorders (3)  ·  Mood Disorders (3)  ·  Nervous System Diseases (3)  ·  Behavior (2)  ·  Chemically-Induced Disorders (2)  ·  Neurologic Manifestations (2)  ·  Pathological Conditions, Signs and Symptoms (2)  ·  Personality Disorders (2)  ·  Signs and Symptoms (2)  ·  Behavioral Symptoms (1)  ·  Body Weight (1)  ·  Central Nervous System Diseases (1)  ·  Child Development Disorders, Pervasive (1)

Interventions

Paliperidone Palmitate (5)  ·  7-chloro-N-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide (1)  ·  AVL3288 (1)  ·  Acetylcysteine (1)  ·  Amantadine (1)  ·  Asian ginseng (1)  ·  Ceftriaxone (1)  ·  Dexmedetomidine (1)  ·  Dronabinol (1)  ·  Geritol (1)  ·  Glycine (1)  ·  Lu AF35700 (1)  ·  Methotrexate (1)  ·  Minocycline (1)  ·  Modafinil (1)

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (4)  ·  Luye Pharma Group Ltd. (4)  ·  New York State Psychiatric Institute (3)  ·  Pakistan Institute of Living and Learning (3)  ·  Dartmouth-Hitchcock Medical Center (2)  ·  North Suffolk Mental Health Association (2)  ·  University of North Carolina, Chapel Hill (2)  ·  Yale University (2)  ·  Alkermes, Inc. (1)  ·  Beth Israel Deaconess Medical Center (1)  ·  Center for Social Innovation, Massachusetts (1)  ·  Eli Lilly and Company (1)  ·  FORUM Pharmaceuticals Inc (1)  ·  H. Lundbeck A/S (1)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)

Countries

United States (28)  ·  Pakistan (3)  ·  Croatia (2)  ·  Spain (2)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Czechia (1)  ·  Hong Kong (1)  ·  Mexico (1)  ·  Puerto Rico (1)  ·  Russia (1)  ·  Slovakia (1)  ·  South Africa (1)

Top investigators

A. Eden Evins, M.D., M.P.H. (1)  ·  Alan I Green, MD (1)  ·  Amy Sun, MD PhD (1)  ·  Andrew Prescot, Ph.D. (1)  ·  Brian A Fallon, MD (1)  ·  Cort A Pedersen, MD (1)  ·  David L Penn, PhD (1)  ·  David Walling, PhD (1)  ·  Dr.Inti Qurashi, MD (1)  ·  Imran B Chaudhry, MD (1)  ·  Jeffrey A Lieberman, M.D. (1)  ·  Jeffrey A Lieberman, MD (1)  ·  Jeffrey Olivet, MA (1)

Results publications

PMID 38244179, PMID 20537128, PMID 20537130, PMID 24419307, PMID 24423017, PMID 25563714, PMID 26072311, PMID 26187603, PMID 26911397, PMID 27089154, PMID 36931838

NIH funding

K23DA018203 (1), R01DA013196 (1), R01DA026799 (1), R01MH093529 (1), R01MH113557 (1), R01MH139651 (1), R21DA030763 (1), R21MH123870 (1), U01MH094247 (1), UL1TR000067 (1)